AI Article Synopsis
- Aromatase inhibitors are the preferred treatment for estrogen/progesterone receptor-positive breast cancer in postmenopausal women, targeting the enzyme responsible for estrogen production.
- Various clinical trials demonstrate the effectiveness of these inhibitors, but some patients struggle with adherence due to drug interactions and side effects.
- Providing education on how to manage side effects and the importance of adherence is crucial for improving treatment outcomes.
Article Abstract
Aromatase inhibitors are the drug of choice for the treatment of estrogen receptor- or progesterone receptor-positive breast cancer in postmenopausal women. Aromatase is an enzyme that catalyzes the final and rate-limiting step in the biosynthesis of estrogen. Inhibitors of this enzyme are an effective therapy for breast cancer. The benefits of these agents have been clearly shown through various clinical trials, yet adherence may be challenging for some patients due to issues of drug interactions, proper first dose education, and adverse effects. Education to prevent and treat adverse effects is of the utmost importance to promote adherence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848814 | PMC |
| http://dx.doi.org/10.6004/jadpro.2020.11.2.6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!